Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - captopril - tablets - 12.5 milligram - ace inhibitors, plain

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - captopril - tablets - 25 milligram - ace inhibitors, plain

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - captopril - tablets - 50 milligram - ace inhibitors, plain

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; hyprolose; polysorbate 80; light magnesium oxide; macrogol 6000; lactose monohydrate; macrogol 400; silicon dioxide; crospovidone; pregelatinised maize starch; iron oxide red; hypromellose phthalate; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; purified talc; titanium dioxide; hypromellose; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: povidone; iron oxide red; crospovidone; hypromellose phthalate; hyprolose; lactose monohydrate; macrogol 400; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; microcrystalline cellulose; macrogol 6000; pregelatinised maize starch; glyceryl monostearate; polysorbate 80; light magnesium oxide; silicon dioxide; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: light magnesium oxide; pregelatinised maize starch; glyceryl monostearate; macrogol 6000; hypromellose phthalate; crospovidone; silicon dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); iron oxide red; macrogol 400; polysorbate 80; microcrystalline cellulose; povidone; lactose monohydrate; purified talc; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; microcrystalline cellulose; povidone; silicon dioxide; macrogol 400; macrogol 6000; hyprolose; pregelatinised maize starch; hypromellose phthalate; iron oxide red; crospovidone; purified talc; light magnesium oxide; polysorbate 80; titanium dioxide; hypromellose; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; hyprolose; polysorbate 80; light magnesium oxide; macrogol 6000; macrogol 400; silicon dioxide; crospovidone; pregelatinised maize starch; iron oxide red; hypromellose phthalate; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; purified talc; titanium dioxide; hypromellose; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: povidone; iron oxide red; crospovidone; hypromellose phthalate; hyprolose; macrogol 400; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; microcrystalline cellulose; macrogol 6000; pregelatinised maize starch; glyceryl monostearate; polysorbate 80; light magnesium oxide; silicon dioxide; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: light magnesium oxide; pregelatinised maize starch; glyceryl monostearate; macrogol 6000; hypromellose phthalate; crospovidone; silicon dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); iron oxide red; macrogol 400; polysorbate 80; microcrystalline cellulose; povidone; purified talc; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer